Adverse events using shorter MDR-TB regimens: outcor Guinea

Public Health Action

11, 2-4

DOI: 10.5588/pha.20.0026

Citation Report

#	Article	IF	CITATIONS
2	Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings. Tuberculosis and Lung Diseases, 2022, 100, 56-65.	0.7	1
3	The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Frontiers in Pharmacology, 0, 14, .	3.5	O